

MIT Biological Research Registration Categories and Experiments

Categories III-D to III-F (most common research):

Category	III-D	III-E	III-F
Definition	<ul style="list-style-type: none"> Modifying pathogens or work with DNA from pathogens DNA/RNA virus work Viral vectors Modifying animals or microorganisms going into animals Modifying weeds, exotic plants, or plant pathogens Certain influenza studies Large scale GMO research (>10L volume) 	<ul style="list-style-type: none"> Eukaryotic virus work (<2/3 of viral genome) in tissue culture at BL1 containment Modifying domestic, non-weed plants or non-pathogenic organisms in plants Transgenic mouse work at BL1 containment Anything else not covered by Categories III A-D or III-F 	<ul style="list-style-type: none"> Material that can't replicate in living cells or can't enter living cells Low risk material already found in nature Transposons found in nature Work with specific non-pathogenic organisms
Examples	<ul style="list-style-type: none"> Cloning GFP plasmid into <i>P. aeruginosa</i> CrispR-Cas9 modification of <i>H. pylori</i> Using modified <i>P. falciparum</i> purchased from ATCC Cloning <i>S. typhimurum</i> genes into <i>E. coli BL21</i> Packaging a 3rd generation lentiviral vector in HEK cells Using GFP to make fluorescent mice Injecting modified HeLa cells into mice Feeding mice <i>L. reuteri</i> containing GFP Growing 11L of <i>E. coli K12</i> with YFP Generating a new novel strain of influenza by combining fragments from different seasonal strains 	<ul style="list-style-type: none"> Modifying Arabidopsis Adding <i>B. subtilis</i> with GFP to the soil of spinach Creating transgenic mice requiring only BL1 containment Cloning GFP in <i>E. coli BL21</i> 	<ul style="list-style-type: none"> Agents containing less than 1/2 of any eukaryotic virus propagated & maintained in cells in tissue culture GMO of <i>E. coli K-12</i>, <i>S. cerevisiae</i>, <i>S. uvarum</i>, <i>K. lactis</i>, or <i>B. subtilis</i> strains
Approvals for amendments	<ul style="list-style-type: none"> EHS Biosafety CAB/ESCRO Project initiation 	<ul style="list-style-type: none"> EHS Biosafety Administrative approval* Project initiation CAB/ESCRO Project continuation 	<ul style="list-style-type: none"> EHS Biosafety Administrative approval* Project initiation CAB/ESCRO Project continuation

*Administrative approval can give be given at discretion of Institutional Biosafety Officer.

MIT Biological Research Registration Categories and Experiments

Categories III-A to III-C (less common experiments that require additional approval):

Category	III-A	III-B	III-C
Definition	<ul style="list-style-type: none"> Making a pathogen resistant to an antibiotic used as a primary method to treat the infection 	<ul style="list-style-type: none"> Adding toxin genes into an organism Specific experiments considered "Major Actions" by the NIH 	<ul style="list-style-type: none"> Gene therapy or clinical studies with recombinant material in human subjects
Examples	<ul style="list-style-type: none"> Making Staphylococcus aureus resistant to doxycycline Making Clostridium difficile resistant to vancomycin 	<ul style="list-style-type: none"> Cloning botulinum toxin into Escherichia coli BL21 Cloning tetanus toxin into Staphylococcus aureus Please see the NIH guidelines for specific examples of Major Actions. 	<ul style="list-style-type: none"> Initiating a clinical research experiment to test the efficacy of a retroviral vector targeting a specific disease Introducing CRISPR-Cas9 to human patients to target a cancer gene
Approval Process	<ul style="list-style-type: none"> EHS Biosafety CAB/ESCRO NIH review Project initiation 	<ul style="list-style-type: none"> EHS Biosafety CAB/ESCRO NIH review Project initiation 	<ul style="list-style-type: none"> EHS Biosafety CAB/ESCRO and COUHES NIH review Project initiation